2003
Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R, Investigators C. Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 42: 971-977. PMID: 13678914, DOI: 10.1016/s0735-1097(03)00911-2.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationRoutine stentingRoutine stent placementStent implantationStent placementPrimary percutaneous transluminal coronary angioplastyComposite adverse event rateLate Angioplasty Complications (CADILLAC) trialRoutine stent implantationAdverse event ratesTransluminal coronary angioplastyRelevant treatment modalitiesRate of deathCADILLAC trialControlled AbciximabEligible lesionsAngiographic restenosisVessel revascularizationComplications TrialCoronary angioplastyDiameter stenosisPTCA results
2002
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. New England Journal Of Medicine 2002, 346: 957-966. PMID: 11919304, DOI: 10.1056/nejmoa013404.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCombined Modality TherapyCoronary AngiographyFemaleHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecurrenceStentsStrokeConceptsPrimary percutaneous transluminal coronary angioplastyAcute myocardial infarctionPercent of patientsPrimary end pointInfarct-related arteryRate of deathMyocardial infarctionAbciximab therapyReperfusion strategyPlatelet glycoprotein IIb/IIIa inhibitorsGlycoprotein IIb/IIIa inhibitorsTarget vesselIIb/IIIa inhibitorsPercutaneous transluminal coronary angioplastyEnd pointComposite of deathTarget vessel revascularizationIschemia-driven revascularizationTransluminal coronary angioplastyComparison of AngioplastyAbciximab useRecurrent ischemiaExperienced centersCoronary angioplastyCoronary stenting
2001
Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial)
Brodie B, Stone G, Morice M, Cox D, Garcia E, Mattos L, Boura J, O’Neill W, Stuckey T, Milks S, Lansky A, Grines C, Group F. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). The American Journal Of Cardiology 2001, 88: 1085-1090. PMID: 11703949, DOI: 10.1016/s0002-9149(01)02039-2.Peer-Reviewed Original ResearchConceptsPrimary percutaneous transluminal coronary angioplastyPrimary PTCAAcute myocardial infarctionCardiogenic shockCoronary angioplastyMyocardial infarctionMyocardial Infarction (TIMI) grade 3 flowPercutaneous transluminal coronary angioplastyInfarct artery reocclusionStent-PAMI trialGrade 3 flowPrimary coronary angioplastyTransluminal coronary angioplastyTriage of patientsArtery reocclusionMortality benefitSurvival benefitEjection fractionLate reperfusionClinical outcomesMyocardial salvageThrombolytic therapyReperfusionPatientsLack of correlation